Page 94 - EJMO-9-2

Eurasian Journal of Medicine and
Oncology
Cancer pathway ranking through odds ratios

inflammation, and cancer. Cell. 2010;140(6):883-899. in human cancers. Cell Cycle. 2004;3(10):1221-1224.
doi: 10.1016/j.cell.2010.01.025 doi: 10.4161/cc.3.10.1164
25. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. 33. Rychahou PG, Kang J, Gulhati P, et al. Akt2 overexpression
Anti-TNF-alpha therapies: The next generation. Nat Rev plays a critical role in the establishment of colorectal cancer
Drug Discov. 2003;2(9):736-746. metastasis. Proc Natl Acad Sci. 2008;105(51):20315-20320.
doi: 10.1038/nrd1175 doi: 10.1073/pnas.0810715105
26. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for 34. Cheng GZ, Zhang W, Wang LH. Regulation of cancer cell
PIK3CA-mutated, hormone receptor-positive advanced survival, migration, and invasion by Twist: AKT2 comes to
breast cancer. New Engl J Med. 2019;380(20):1929-1940. interplay. Cancer Res. 2008;68(4):957-960.
doi: 10.1056/NEJMoa1813904 doi: 10.1158/0008-5472.CAN-07-5067
27. Balkwill F. TNF-alpha in promotion and progression of 35. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: Divergent
cancer. Cancer Metastasis Rev. 2006;25:409-416. roles of isoforms, modes of activation and therapeutic
doi: 10.1007/s10555-006-9005-3 targeting. Nat Rev Cancer. 2015;15(1):7-24.
28. Hanauske AR, Sundell K, Lahn M. The role of protein kinase doi: 10.1038/nrc3860
C-alpha (PKC-alpha) in cancer and its modulation by the 36. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte
novel PKC-alpha-specific inhibitor aprinocarsen. Curr development, differentiation and activation. Nat Rev
Pharm Des. 2004;10(16):1923-1936. Immunol. 2003;3(4):317-330.
doi: 10.2174/1381612043384376 doi: 10.1038/nri1056
29. Omerovic J, Prior IA. Compartmentalized signalling: 37. Liu Y, Wang D, Li Z, et al. Pan-cancer analysis on the
Ras proteins and signalling nanoclusters. FEBS J. role of PIK3R1 and PIK3R2 in human tumors. Sci
2009;276(7):1817-1825. Rep. 2022;12(1):5924.
doi: 10.1111/j.1742-4658.2009.06928.x doi: 10.1038/s41598-022-09889-0
30. Vivanco I, Sawyers CL. The phosphatidylinositol 38. Tan AC. Targeting the PI3K/Akt/mTOR pathway in
3-kinase-AKT pathway in human cancer. Nat Rev Cancer. non‐small cell lung cancer (NSCLC). Thorac Cancer.
2002;2(7):489-501.
2020;11(3):511-518.
doi: 10.1038/nrc839
doi: 10.1111/1759-7714.13328
31. Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic 39. Csermely P, London A, Wu LY, Uzzi B. Structure and
target for cancer. Cancer Res. 2019;79(6):1019-1031.
dynamics of core/periphery networks. J Complex Netw.
doi: 10.1158/0008-5472.CAN-18-2738 2013;1(2):93-123.
32. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA doi: 10.1093/comnet/cnt016

Volume 9 Issue 2 (2025) 86 doi: 10.36922/ejmo.8082